Becton, Dickinson and Company (BDX) investor relations material

Leadership and strategy

• Newly appointed CFO emphasizes consistency, transparency, and responsible capital allocation, prioritizing share buybacks and tuck-in acquisitions to drive growth and maintain leverage at 2.5x.

• The leadership team is focused on sharpening strategic execution rather than transforming the business, aiming to deliver on promised financial targets.

• Operational rigor is highlighted, leveraging decades of experience across regions and business segments to support the BD 2025 strategy.

Portfolio evolution and growth drivers

• The portfolio has been reshaped over five years, with divestitures in diabetes care and life sciences, and a focus on med tech, now $19B versus $4.5B a decade ago.

• Growth is driven by segments like advanced patient monitoring, biopharma solutions (biologics now 55% of segment revenue), and interventional products such as PureWick and tissue regeneration, all showing double-digit growth.

• Medical essentials remain a stable, recurring revenue base, generating cash for reinvestment and share buybacks.

Portfolio growth segmentation

• About 30% of the portfolio is growing at double digits, 25-30% at mid-single digits, and 30% (medical essentials) at low single digits.

• 10% of the portfolio faces declines due to headwinds in China, Alaris, and vaccines, with ongoing investments to elevate mid-single digit growth areas.